Precision Therapy Assessments

Precision Therapy Assessments are comprehensive health technology assessments evaluating therapies, which target genes, proteins, and other molecules, or are guided by molecular testing, such as specialty drugs and gene therapies.

Used in conjunction with our Laboratory Insights database, these reports provide the critical evidence context for the use of genetic tests, including panel tests. These reports include the Hayes Rating to indicate the overall strength and direction of the body of evidence for the precision therapy.

Precision Therapy Assessments provide evidence-based support for the development of coverage policy, utilization management, and evidence-based clinical practices. Reports are reviewed annually up to 5 years post publication to determine if there is new literature or evidence that would impact a change in rating and warrant an updated report.

Lutetium Lu 177 Dotatate (Lutathera, Advanced Accelerator Applications USA Inc) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Health Problem: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms derived from neuroendocrine cells within the gastrointestinal tract and pancreas, where curative surgery options are limited. GEP-NETs are estimated to affect approximately 3 individuals per 100,000 people per year.

read more

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Obesity in Women with Polycystic Ovary Syndrome

Health Problem: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6% to 20% of women of reproductive age. It is characterized by oligoovulation (menstrual irregularity), hyperandrogenism (increased testosterone levels), and polycystic ovaries. Obesity is a common feature of PCOS, affecting approximately 40% to 80% of w…

read more